Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.
Ontology highlight
ABSTRACT: The tumour necrosis factor family member TNF-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in a variety of cancer cells through the activation of death receptors 4 (DR4) and 5 (DR5) and is considered a promising anticancer therapeutic agent. As apoptosis seems to occur primarily via only one of the two death receptors in many cancer cells, the introduction of DR selectivity is thought to create more potent TRAIL agonists with superior therapeutic properties. By use of a computer-aided structure-based design followed by rational combination of mutations, we obtained variants that signal exclusively via DR4. Besides an enhanced selectivity, these TRAIL-DR4 agonists show superior affinity to DR4, and a high apoptosis-inducing activity against several TRAIL-sensitive
SUBMITTER: Reis CR
PROVIDER: S-EPMC3035906 | biostudies-literature | 2010 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA